About NeoGenomics (NASDAQ:NEO)
NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services that focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clients' oncology programs, as well as acts as a reference laboratory supplying anatomic pathology testing services. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
Industry, Sector and Symbol
Industry Testing laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NEO
CUSIPN/A
Phone239-768-0600
Debt
Debt-to-Equity Ratio0.56%
Current Ratio2.42%
Quick Ratio2.21%
Price-To-Earnings
Trailing P/E Ratio154.50
Forward P/E Ratio92.70
P/E Growth4.77
Sales & Book Value
Annual Sales$258.61 million
Price / Sales2.89
Cash Flow$0.4801 per share
Price / Cash19.31
Book Value$2.15 per share
Price / Book4.31
Profitability
EPS (Most Recent Fiscal Year)$0.06
Net Income$-840,000.00
Net Margins-1.37%
Return on Equity4.34%
Return on Assets2.15%
Miscellaneous
Employees1,030
Outstanding Shares80,510,000
NeoGenomics (NASDAQ:NEO) Frequently Asked Questions
What is NeoGenomics' stock symbol?
NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."
How were NeoGenomics' earnings last quarter?
NeoGenomics (NASDAQ:NEO) announced its earnings results on Wednesday, February, 21st. The medical research company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.02. The medical research company had revenue of $67.79 million for the quarter, compared to the consensus estimate of $66.32 million. NeoGenomics had a negative net margin of 1.37% and a positive return on equity of 4.34%. The company's revenue was up 12.1% on a year-over-year basis. During the same period in the previous year, the business earned $0.05 EPS. View NeoGenomics' Earnings History.
When is NeoGenomics' next earnings date?
What guidance has NeoGenomics issued on next quarter's earnings?
NeoGenomics issued an update on its FY18 earnings guidance on Wednesday, February, 21st. The company provided earnings per share (EPS) guidance of $0.15-0.20 for the period, compared to the Thomson Reuters consensus estimate of $0.21.
What price target have analysts set for NEO?
7 brokerages have issued 12 month price objectives for NeoGenomics' stock. Their predictions range from $9.00 to $24.00. On average, they expect NeoGenomics' stock price to reach $17.2857 in the next year. View Analyst Ratings for NeoGenomics.
Who are some of NeoGenomics' key competitors?
Some companies that are related to NeoGenomics include Irhythm Technologies (IRTC), Ensign Group (ENSG), Pacira Pharmaceuticals (PCRX), Zogenix (ZGNX), Audentes Therapeutics (BOLD), Varex Imaging (VREX), Immuron (IMRN), AxoGen (AXGN), iKang Healthcare Group (KANG), DBV Technologies (DBVT), ImmunoGen (IMGN), LHC Group (LHCG), Accelerate Diagnostics (AXDX), Iovance Biotherapeutics (IOVA), Prothena (PRTA), Medpace (MEDP), Drägerwerk (DRW3) and Brookdale Senior Living (BKD).
Who are NeoGenomics' key executives?
NeoGenomics' management team includes the folowing people:
- Mr. Douglas M. VanOort, Chairman & CEO (Age 63)
- Mr. Steven C. Jones, Exec. VP, Chief Compliance Officer & Director (Age 55)
- Dr. Maher Albitar, Sr. VP, Chief Medical Officer and Director of R&D (Age 63)
- Dr. Steven G. Brodie, VP of Operations & Pres of Pharma Services Division (Age 57)
- Mr. George A. Cardoza, Pres of Pharma Services Division (Age 56)
Has NeoGenomics been receiving favorable news coverage?
News articles about NEO stock have been trending somewhat positive on Saturday, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. NeoGenomics earned a news impact score of 0.18 on Accern's scale. They also assigned headlines about the medical research company an impact score of 47.07 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
How do I buy shares of NeoGenomics?
Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NeoGenomics' stock price today?
One share of NEO stock can currently be purchased for approximately $9.27.
How big of a company is NeoGenomics?
NeoGenomics has a market capitalization of $742.28 million and generates $258.61 million in revenue each year. The medical research company earns $-840,000.00 in net income (profit) each year or $0.06 on an earnings per share basis. NeoGenomics employs 1,030 workers across the globe.
How can I contact NeoGenomics?
NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at 239-768-0600 or via email at [email protected]
MarketBeat Community Rating for NeoGenomics (NEO)
MarketBeat's community ratings are surveys of what our community members think about NeoGenomics and other stocks. Vote "Outperform" if you believe NEO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEO will underperform the S&P 500 over the long term. You may vote once every thirty days.
NeoGenomics (NASDAQ:NEO) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for NeoGenomics in the last 12 months. Their average twelve-month price target is $17.2857, suggesting that the stock has a possible upside of 86.47%. The high price target for NEO is $24.00 and the low price target for NEO is $9.00. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Hold |
| Consensus Rating Score: | 2.86 | 2.71 | 2.71 | 2.25 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $17.2857 | $17.2857 | $15.8333 | $10.3333 |
| Price Target Upside: | 86.47% upside | 102.88% upside | 81.57% upside | 2.88% downside |
NeoGenomics (NASDAQ:NEO) Consensus Price Target History
NeoGenomics (NASDAQ:NEO) Analyst Ratings History
Show:
(Data available from 4/21/2016 forward)
NeoGenomics (NASDAQ:NEO) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
NeoGenomics (NASDAQ NEO) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 11.20%
Institutional Ownership Percentage: 84.63%
NeoGenomics (NASDAQ NEO) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 7/27/2017 | Alison L Hannah | Director | Buy | 20,000 | $9.19 | $183,800.00 | 38,782 |  |
| 6/22/2017 | Jennifer Balliet | VP | Sell | 10,723 | $8.49 | $91,038.27 | | |
| 6/5/2017 | Steven A Ross | Insider | Sell | 70,833 | $7.76 | $549,664.08 | 4,500 | |
| 5/26/2017 | Jennifer Balliet | VP | Sell | 3,334 | $7.50 | $25,005.00 | 10,049 | |
| 3/20/2017 | Steven G Brodie | Insider | Sell | 50,000 | $7.93 | $396,500.00 | 49,403 | |
| 9/23/2016 | Maher Albitar | Insider | Sell | 2,800 | $8.40 | $23,520.00 | | |
| 9/20/2016 | Maher Albitar | Insider | Sell | 105,300 | $8.20 | $863,460.00 | 105,300 | |
| 9/12/2016 | Maher Albitar | Insider | Sell | 60,075 | $8.23 | $494,417.25 | 165,375 | |
| 8/19/2016 | Maher Albitar | Insider | Sell | 370,000 | $8.23 | $3,045,100.00 | 263,492 | |
| 5/27/2016 | Oort Douglas M Van | CEO | Sell | 481,387 | $8.73 | $4,202,508.51 | 1,675,000 | |
| 5/18/2016 | Steven A Ross | Insider | Sell | 18,000 | $8.50 | $153,000.00 | 4,500 | |
| 5/9/2016 | Steven A Ross | Insider | Sell | 15,000 | $8.22 | $123,300.00 | 4,500 | |
| 5/2/2016 | Steven C Jones | VP | Sell | 177,745 | $8.21 | $1,459,286.45 | 266,251 | |
| 4/29/2016 | Steven A Ross | Insider | Sell | 112,500 | $8.11 | $912,375.00 | 117,000 | |
| 3/11/2016 | George Cardoza | CFO | Sell | 32,000 | $6.83 | $218,560.00 | 221,089 | |
| 3/9/2016 | Oort Douglas M Van | CEO | Sell | 450,000 | $7.10 | $3,195,000.00 | 2,125,000 | |
| 3/3/2016 | Alison L Hannah | Director | Buy | 10,000 | $6.90 | $69,000.00 | 11,560 | |
| 12/7/2015 | Lynn A Tetrault | Director | Buy | 3,500 | $7.72 | $27,020.00 | 5,060 | |
| 12/3/2015 | Robert J Shovlin | COO | Buy | 6,550 | $7.75 | $50,762.50 | 6,550 | |
| 11/27/2015 | Steven C Jones | VP | Sell | 385,000 | $8.09 | $3,114,650.00 | 286,251 | |
| 11/2/2015 | Bruce K Crowther | Director | Buy | 6,400 | $7.81 | $49,984.00 | | |
| 12/19/2014 | Robert H Horel | VP | Sell | 32,389 | $4.21 | $136,357.69 | | |
| 12/18/2014 | Robert H Horel | VP | Sell | 62,893 | $4.20 | $264,150.60 | | |
| 12/4/2014 | Michael T Dent | Director | Sell | 11,800 | $4.50 | $53,100.00 | | |
| 11/26/2014 | George Cardoza | CFO | Sell | 60,000 | $4.28 | $256,800.00 | | |
| 11/21/2014 | Michael T Dent | Director | Sell | 33,200 | $4.51 | $149,732.00 | | |
| 5/22/2014 | Robert P Gasparini | Insider | Sell | 100,000 | $3.49 | $349,000.00 | | |
| 5/19/2014 | Robert Gasparini | Insider | Sell | 10,000 | $3.65 | $36,500.00 | 8,439 | |
| 3/28/2014 | Maher Albitar | Insider | Buy | 14,492 | $3.51 | $50,866.92 | | |
| 3/5/2014 | Michael T Dent | Director | Sell | 300,000 | $3.00 | $900,000.00 | | |
| 12/11/2013 | Robert P Gasparini | Insider | Sell | 20,100 | $3.70 | $74,370.00 | | |
| 12/9/2013 | George Cardoza | CFO | Sell | 20,000 | $3.66 | $73,200.00 | | |
| 12/5/2013 | Robert P Gasparini | Insider | Sell | 32,996 | $3.67 | $121,095.32 | | |
| 12/3/2013 | Robert P Gasparini | Insider | Sell | 32,146 | $3.67 | $117,975.82 | | |
| 11/25/2013 | Steven C Jones | VP | Sell | 112,969 | $3.58 | $404,429.02 | | |
| 4/30/2013 | Steven C Jones | Director | Sell | 100,000 | $3.71 | $371,000.00 | | |
(Data available from 1/1/2013 forward)
NeoGenomics (NASDAQ NEO) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | NeoGenomics (NEO) versus Intertek Group (IKTSY) Critical Analysis
www.americanbankingnews.com - April 18 at 1:34 PM |
| NeoGenomics (NEO) Upgraded by BidaskClub to Buy
www.americanbankingnews.com - April 18 at 9:51 AM |
| NeoGenomics (NEO) Upgraded at BidaskClub
www.americanbankingnews.com - April 17 at 1:54 PM |
| NeoGenomics (NEO) Upgraded by ValuEngine to Buy
www.americanbankingnews.com - April 17 at 10:29 AM |
 | BTIG Upgrades Neogenomics (NEO) to Buy
www.streetinsider.com - April 16 at 8:46 AM |
| NeoGenomics (NEO) Rating Increased to Buy at BTIG Research
www.americanbankingnews.com - April 16 at 7:39 AM |
| NeoGenomics, Inc. (NEO) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - April 11 at 7:35 PM |
| Contrasting Intertek Group (IKTSY) and NeoGenomics (NEO)
www.americanbankingnews.com - April 10 at 9:21 AM |
| Analysts Anticipate NeoGenomics, Inc. (NEO) Will Post Quarterly Sales of $64.04 Million
www.americanbankingnews.com - April 10 at 3:30 AM |
| Analysts Anticipate NeoGenomics, Inc. (NEO) to Post $0.03 EPS
www.americanbankingnews.com - April 8 at 1:22 PM |
| NeoGenomics (NEO) Cut to "Buy" at BidaskClub
www.americanbankingnews.com - April 6 at 7:03 PM |
| NeoGenomics (NEO) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - April 4 at 11:26 PM |
| Head to Head Review: NeoGenomics (NEO) & Intertek Group (IKTSY)
www.americanbankingnews.com - April 3 at 11:39 PM |
 | NeoGenomics Schedules its First Quarter Earnings Release for May 1, 2018
feeds.benzinga.com - April 2 at 5:46 PM |
| Analyzing Intertek Group (IKTSY) & NeoGenomics (NEO)
www.americanbankingnews.com - April 2 at 9:14 AM |
| NeoGenomics (NEO) versus Intertek Group (IKTSY) Head to Head Comparison
www.americanbankingnews.com - April 2 at 1:32 AM |
| Reviewing NeoGenomics (NEO) and Its Rivals
www.americanbankingnews.com - March 28 at 5:28 PM |
| NeoGenomics (NEO) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - March 27 at 3:28 PM |
| NeoGenomics (NEO) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - March 25 at 2:34 PM |
| NeoGenomics (NEO) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - March 24 at 3:56 PM |
| Analysts Expect NeoGenomics, Inc. (NEO) Will Post Quarterly Sales of $64.04 Million
www.americanbankingnews.com - March 24 at 7:54 AM |
| NeoGenomics, Inc. (NEO) Expected to Post Earnings of $0.03 Per Share
www.americanbankingnews.com - March 22 at 1:28 PM |
 | Global Cancer/Tumor Profiling Market Report 2017 Analysis & Forecasts 2013-2023 - Rising Utility of Biomarkers in ... - PR Newswire (press release)
www.prnewswire.com - March 20 at 4:51 PM |
 | NeoGenomics Announces Executive Appointments
finance.yahoo.com - March 20 at 9:03 AM |
| Research Report Identifies Chatham Lodging Trust (REIT), Independent Bank Group, NeoGenomics, Black Knight, Aethlon Medical, and PRA Group with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
finance.yahoo.com - March 19 at 8:58 AM |
| NeoGenomics, Inc. (NEO) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - March 17 at 7:38 PM |
| NeoGenomics (NEO) Given New $24.00 Price Target at Canaccord Genuity
www.americanbankingnews.com - March 13 at 5:17 PM |
| Scotiabank Increases NeoGenomics (NEO) Price Target to $23.00
www.americanbankingnews.com - March 13 at 5:16 PM |
| NeoGenomics (NEO) Given New $24.00 Price Target at Royal Bank of Canada
www.americanbankingnews.com - March 13 at 5:16 PM |
| NeoGenomics (NEO) Lowered to "Sell" at ValuEngine
www.americanbankingnews.com - March 11 at 11:42 PM |
| NeoGenomics, Inc. (NEO) Expected to Announce Quarterly Sales of $64.04 Million
www.americanbankingnews.com - March 7 at 4:27 PM |
| SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating NeoGenomics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
www.prnewswire.com - March 7 at 7:49 AM |
| NeoGenomics, Inc. (NEO) Shares Bought by Ranger Investment Management L.P.
www.americanbankingnews.com - March 6 at 2:10 PM |
| Next Century Growth Investors LLC Sells 905,209 Shares of NeoGenomics, Inc. (NEO)
www.americanbankingnews.com - March 2 at 5:58 PM |
| Form 4 NEOGENOMICS INC For: Feb 26 Filed by: SHOVLIN ROBERT J. - StreetInsider.com
www.streetinsider.com - March 2 at 5:40 PM |
| NeoGenomics, Inc. (NEO) Shares Sold by Hudson Bay Capital Management LP
www.americanbankingnews.com - March 2 at 1:32 PM |
| NeoGenomics, Inc. (NEO) Holdings Cut by Cortina Asset Management LLC
www.americanbankingnews.com - March 1 at 11:53 AM |
| Royce & Associates LP Sells 60,000 Shares of NeoGenomics, Inc. (NEO)
www.americanbankingnews.com - February 28 at 9:34 AM |
| NeoGenomics (NEO) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - February 23 at 10:06 AM |
| NeoGenomics (NEO) Announces Earnings Results
www.americanbankingnews.com - February 21 at 9:21 AM |
| NeoGenomics (NEO) Releases FY18 Earnings Guidance
www.americanbankingnews.com - February 21 at 9:08 AM |
| NeoGenomics, Inc. (NEO)
finance.yahoo.com - February 21 at 8:52 AM |
| NeoGenomics Reports Revenue of $67.8 Million on 18.7% Clinical Volume Growth and $10.5 Million of Adjusted EBITDA in the Fourth Quarter of 2017
finance.yahoo.com - February 21 at 8:52 AM |
| NeoGenomics beats Street 4Q forecasts
finance.yahoo.com - February 21 at 8:52 AM |
| NeoGenomics, Inc. (NEO) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - February 20 at 7:44 PM |
| Zacks: Brokerages Anticipate NeoGenomics, Inc. (NEO) Will Announce Quarterly Sales of $65.83 Million
www.americanbankingnews.com - February 18 at 2:38 AM |
| NeoGenomics (NEO) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - February 14 at 2:56 AM |
| Zacks: Analysts Expect NeoGenomics, Inc. (NEO) Will Announce Quarterly Sales of $65.83 Million
www.americanbankingnews.com - February 1 at 5:10 AM |
| NeoGenomics Schedules its Fourth Quarter and Fiscal Year 2017 Earnings Release for February 21, 2018
feeds.benzinga.com - January 30 at 8:20 AM |
| NeoGenomics, Inc. (NEO) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - January 26 at 7:28 PM |
NeoGenomics (NASDAQ:NEO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
NeoGenomics (NASDAQ:NEO) Income Statement, Balance Sheet and Cash Flow Statement
NeoGenomics (NASDAQ NEO) Stock Chart for Saturday, April, 21, 2018
Loading chart…
